# Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

> **NCT07353268** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tao Zhang** · enrollment: 76 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART)
- **DRUG:** Standard Third-Line Therapy

## Key facts

- **NCT ID:** NCT07353268
- **Lead sponsor:** Tao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-21
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07353268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07353268, "Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07353268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*